activation by 4Life Transfer Factor Advanced Formula, 4Life Transfer Factor Plus Advanced Formula and IL-2 resulted ina kill rate of K562 cancer cells of 69%, 97% and 88% respectively with the 48-hour incubation period giving the greatestNK cell activation.
As a Result of These Tests 4Life® Transfer Factor™ Is Now Approved By the Health Ministry of Russia for use in Hospitals and Clinics! The
First Ever Dietary Supplement to be approved for Useby Doctors and Hospitals in Russia
SANDY, UT (October 1, 2004) - 4Life announced today that 4Life Transfer Factor products as immunemodulators have been approved for use in hospitals and clinics in the Russian Federation.
Theresults of ten separate clinical trials and two experimental studies on 4Life Transfer Factor products werecombined in a Methodological Document that was approved by the Ministry of Health, which now allowsdoctors to recommend 4Life Transfer Factor Classic and 4Life Transfer Factor Plus® products to their patients. Transfer Factor is the
First Dietary Supplement Approved for Use by Doctors and Hospitalsin Russia
. The Russian Ministry of Health is the equivalent of the Food and Drug Administration in theUnited States. Doctors and scientists from Russia have been working jointly with scientists from 4Life for several years to arrive at this accomplishment. This approval establishes a new roll of dietary supplementsin the Russian health care system.
Remarkable Response from Russian Academy of Medical Sciences
In another sector of research of 4Life Transfer Factor, Dr. Kisielevsky of the Russian Academy of MedicalSciences stated, “The 4Life sample [Transfer Factor Advanced Formula] activated NK (natural killer) cellactivity more than the Interleukin-2 (IL2) drug we used as the standard.” This discovery has attracted theattention of The International Scientific and Technical Center (ISTC) of Russia.
Scientists from Several Countries Join Forces for Additional Clinical Studies of Transfer Factor
TheISTC of Russia is a member of a joint international project with other health agencies of Japan, Europe andthe US. The objective of the international project is to combine efforts in finding improvedimmunotherapies. Following the discoveries from the NK cell testing, the scientists of 4Life have beeninvited to join the project. 4Life Transfer Factor as an immune modulator will be further researched in thisinternational forum. The cost of the studies will be paid by the ISTC.
Speaking of this benchmark achievement, Dr. Calvin McCausland, VP of Research of 4Life, and Dr. Emma Oganova, 4Life/Eurasia President, jointly expressed that because of theacceptance by such a reputable organization and doctors from Russia and other major countries, 4LifeTransfer Factor will gain wider acceptance in the professional and private sectors as a superior immunesystem enhancing product. The worldwide ramifications to this acceptance are just beginning.4Life is theworld’s foremost leader in the development, production and distribution of natural immune support productsand were recently recognized by
magazine as the fifteenth fastest growing privately held company inAmerica.
*We make no claims that our products will cure an illness. We suggest that you consult a physician if ill. The above statements have not been evaluated by the FDA or our company.www.4lifediscovery.my4life.com